MLL

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023: A New Generation of Proteins that have Found Application as a Therapeutic Target in Several Prevalent Diseases - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, MLL, Marketing, NPM1, Lung cancer, Protein, Indication, Acute lymphoblastic leukemia, MEN1, KMT2A, Research, FDA, EMA, Colorectal cancer, Leukemia, MYC, Diabetes, Menin, Clinical trial, Cancer, Mutation, Pancreatic cancer, Bone marrow, Patient, Acute myeloid leukemia, ALL, Acute leukemia, AML, Osteopathic medicine in Canada, Fast Track, Pharmaceutical industry

The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Menin represents a new generation of proteins that have found application as a therapeutic target in several prevalent diseases, especially cancer.
  • This has generated the need for development of menin inhibitors that can be used to treat these diseases.
  • Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023 Report Highlights:
    Menin Inhibitors Drugs In Clinical Trials: > 10 Drugs
    Global Menin Inhibitors Drugs Clinical Trials By Company, Indication & Phase
    Menin Inhibitors Clinical Research Innovation Trends By Region: US, Europe & Canada

Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Additive effect, Postcholecystectomy syndrome, CRi, JAK, University, ASH, Disease, MLL, Patient, QT, Division, SMPA, Cancer, Acute leukemia, Growth, MD Anderson Cancer Center, Society, Relapse, Blood, Pharmaceutical industry, Leukemia

CAMBRIDGE, Mass., Dec. 11, 2023 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced new data from the ongoing Phase 1/2 first-in-human study of DSP-5336, in patients with relapsed or refractory acute leukemia, presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis.1,2,3 

Key Points: 
  • In the ongoing study, patients are continuing to dose escalate and are now at therapeutic levels.
  • Preliminary results presented at ASH 2023 included four evaluable patients treated with DSP-5336 200 mg twice-daily, three of whom showed objective responses.
  • Inhibition of the menin-MLL protein interaction may be able to reverse the leukemogenic activity of MLL fusion proteins and may be a future therapeutic option for acute leukemia."
  • We look forward to continuing the study of DSP-5336 as a monotherapy and to exploring additional combination studies."

Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities

Retrieved on: 
Monday, July 10, 2023
PIM1, Ruxolitinib, Drug development, Ulotaront, Schizophrenia, Sumitomo Pharma, Research, SMPA, Science, Regenerative medicine, Acute myeloid leukemia, AML, DSM-IV codes, MLL, Patient, Investment, Growth, Health, Psychiatry, Neurology, Urology, Data Analytics Library, Pharmaceutical industry

The newly combined company is focused on addressing unmet patient needs in critical disease areas across psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies.

Key Points: 
  • The newly combined company is focused on addressing unmet patient needs in critical disease areas across psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies.
  • "We are pleased to have successfully completed the combination of Sumitomo Pharma's U.S. subsidiaries to form SMPA," said Hiroshi Nomura, Representative Director, President and Chief Executive Officer of Sumitomo Pharma.
  • "As a Sumitomo Pharma Group growth engine, SMPA will focus on maximizing the value of the three key products early, namely, ORGOVYX®, MYFEMBREE®, and GEMTESA®.
  • We invite you to learn about SMPA's full leadership team and capabilities on our new website: https://www.us.sumitomo-pharma.com .

Aptose Reports Results for the First Quarter 2023

Retrieved on: 
Monday, May 8, 2023
TP53, APS, CRH, NPM1, Aes, Food and Drug Administration, Clinical trial, G1, Absorption, Aplastic anemia, Trial of the century, Acute myeloid leukemia, Phase 1, AML, Running, Drug-related deaths in the United Kingdom, MLL, Patient, RAS, SAN, EHA, RUNX1, IDH, FLT3, TSX, CRi, Toxic leukoencephalopathy, Infrared spectroscopy correlation table, FDA, CRP, Gene, Safety, Pharmaceutical industry, DNMT3A, G3

─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;

Key Points: 
  • ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;
    SAN DIEGO and TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for first quarter ended March 31, 2023, and provided a corporate update.
  • “While it is still too early to report confirmed responses in the APTIVATE trial, it is moving in the right direction.
  • Aptose has identified a safe therapeutic range with a broad therapeutic window, spanning the dose levels of 40, 80, 120 and 160 milligrams.
  • If findings continue as anticipated, Aptose plans to escalate the dose of G3 and seek a dose with robust safety and higher exposure levels.

Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, May 2, 2023
CLL, PDAC, KRAS, Insulin, Food, CRC, Diabetes, Investment, Chronic lymphocytic leukemia, Menin, DLBCL, Multiple myeloma, NPM1, Acute leukemia, CD135, Type 2 diabetes, Mutation, Cancer, NSCLC, Lung cancer, B-cell lymphoma, Acute myeloid leukemia, AML, MLL, Patient, DSM-IV codes, Colorectal cancer, Administration, Education minister, MM, FLT3, Research and development, R, Commonwealth Fusion Systems, Research, Phase, American Diabetes Association, ADA, IND, Safety, Pharmaceutical industry, Medical imaging, Osteopathic medicine in Canada, Glycated hemoglobin

We believe that none of the currently approved therapies for diabetes adequately addresses the beta cell mass and function loss.

Key Points: 
  • We believe that none of the currently approved therapies for diabetes adequately addresses the beta cell mass and function loss.
  • With its intended disease-modifying mechanism of action, BMF-219 could potentially represent a monumental shift for the treatment of patients with diabetes.
  • Reported initial clinical data in March 2023 from the first two cohorts of the Phase II portion of COVALENT-111.
  • Report initial clinical data of AML/ALL patients (including those with MLLr rearrangement and NPM1 mutations) dosed in the COVALENT-101 study in the second quarter of 2023.

Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, March 28, 2023
CLL, PDAC, KRAS, Maintenance, Insulin, Food, CRC, Diabetes, Chronic lymphocytic leukemia, Investment, Menin, Multiple myeloma, NPM1, Type 2 diabetes, Mutation, Cancer, G&A, Liraglutide, Lung cancer, B-cell lymphoma, Mixed-phenotype acute leukemia, Investigational New Drug, MLL, Patient, DSM-IV codes, Colorectal cancer, Administration, MM, FLT3, Research and development, R, Research, Phase, FDA, IND, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, DLBCL, NSCLC, Osteopathic medicine in Canada, Glycated hemoglobin

“During 2022 we transformed Biomea from a preclinical company to a fully integrated clinical-stage company, pursuing ten indications, with two distinct molecules in three different trials.

Key Points: 
  • “During 2022 we transformed Biomea from a preclinical company to a fully integrated clinical-stage company, pursuing ten indications, with two distinct molecules in three different trials.
  • I am incredibly proud of our team’s performance and dedication, which has enabled our rapid clinical progress,” said Thomas Butler, CEO and Chairman of Biomea.
  • None of the currently approved therapies for diabetes are effectively addressing the loss and function of beta cells.
  • G&A expenses were $20.9 million for the year ended December 31, 2022, compared to $13.7 million for the same period in 2021.

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Thursday, March 23, 2023
ASH, Lux, APS, Controller, ITD, TKD, G1, BCR, Associate, Accounting, Plasma, RAS, Investment, Patient, RUNX1, Clinical, LYN, TP53, DNMT3A, SYK, European Hematology Association, Research, Aplastic anemia, MRD, BCL2, PLOS One, MLL, Data, FLT3, TSX, Amylin Pharmaceuticals, FDA, Combination, RSK, Lymphoid leukemia, Absorption, BTK, Acute myeloid leukemia, Phase 1, CR, Hand, MD Anderson Cancer Center, Inflammation, Lymphoma, Phosphorylation, National university, NPM1, Clinical trial, European School, Data monitoring committee, AML, BID, EHA, ISTA Pharmaceuticals, Harvard Business School, Toxic leukoencephalopathy, G3, Gene, Society, Pharmaceutical industry, Cryptocurrency, Vaccine, Running

SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.
  • Total cash and cash equivalents and investments as of December 31, 2022, were $47.0 million.
  • Aptose Appoints VP, Controller – During the fourth quarter, Aptose appointed Brooks Ensign, Vice President and Controller.
  • A summary of the results of operations for the years ended December 31, 2022 and 2021 is presented below:

NEXGEL Partners with Former Major League Lacrosse Player, Greg “The Beast” Gurenlian, and The Face-Off Academy to Fight Turf Burn with Turfguard

Retrieved on: 
Tuesday, March 7, 2023
Partnership, Infection, 2021 Premier Lacrosse League season, Scar, Lacrosse, Athlete, Redwoods Lacrosse Club, FDA, Hospital, Skin, Major League Lacrosse, Pain, MLL, Amazon (company), Steinfeld Trophy, Sports equipment, Greg Gurenlian

LANGHORNE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today it has partnered with former Major League Lacrosse (MLL) player and founder of The Face-off Academy, Greg “The Beast” Gurenlian, to provide athletes with a better treatment for turf burn through the use of NEXGEL’s Turfguard, a unique hydrogel dressing for soothing turf burn and protecting athletic wounds.

Key Points: 
  • Adam Levy, CEO of NEXGEL, said, “We are thrilled to partner with Greg and his team to address the harmful effects of turf burn including, pain, infection and long-term scarring.
  • We look forward to working with Greg and supporting him and other athletes on and off the field with Turfguard for topical recovery.
  • I don’t know a single athlete that hasn’t dealt with turf burn at some point in their careers.
  • Lacrosse players around the country will now get a chance to see how incredibly effective Turfguard is.”

Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

Retrieved on: 
Monday, January 30, 2023
AML, Gene, BCL2, Society, ASH, NRAS, ITD, MLL, TSX, Mutation, SYK, Aplastic anemia, Toxic leukoencephalopathy, Patient, SAN, Clinical trial, NPM1, FDA, MD Anderson Cancer Center, KRAS, RUNX1, TKD, Acute myeloid leukemia, APS, TP53, FLT3, Toxicity, Maintenance, Associate, TKI, Pharmaceutical industry, Vaccine, DNMT3A

SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML). In parallel, another clinical response has been achieved by a R/R AML patient receiving 40 mg tuspetinib once daily orally in the original dose exploration trial, the second response at the recently launched low-dose 40 mg cohort.

Key Points: 
  • SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML).
  • Importantly, Aptose has elucidated a rationale for the superior safety profile of tuspetinib.
  • In the APTIVATE expansion trial, tuspetinib also will be tested in combination with venetoclax.
  • “We are pleased to have dosing underway in our APTIVATE clinical trial of tuspetinib in a very ill R/R AML population,” said William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer.